

UNITED STATES DEPARTMENT OF AGRICULTURE

+ + + + +

NATIONAL ADVISORY COMMITTEE ON
MICROBIOLOGICAL CRITERIA FOR FOODS

+ + + + +

PLENARY SESSION

+ + + + +

August 7, 2018
10:00 a.m.Patriots Plaza III
355 E Street, SW
First Floor Auditorium
Washington, D.C. 20024

CHAIR: CAPT. KIS ROBERTSON HALE
Deputy Assistant Administrator
OPHS/FSIS

VICE CHAIR: DR. MICKEY PARISH
Director of Senior Science Advisor
FDA/CFSAN

MODERATOR: DR. MARK CARTER
Designated Federal Officer
OPHS/FSIS

COMMITTEE MEMBERS:

DR. GARY ACUFF
MR. AARON ASMUS
MS. VANESSA COFFMAN
DR. PEGGY COOK
MS. DE ANN DAVIS
DR. JAMES DICKSON
DR. FRANCISCO DIEZ-GONZALEZ

Free State Reporting, Inc.
1378 Cape St. Claire Road
Annapolis, MD 21409
(410) 974-0947

COMMITTEE MEMBERS: (Continued)

DR. JOSEPH EIFERT
DR. PHILIP ELLIOTT
DR. KATHLEEN GLASS
DR. CAROLYN HOVDE
DR. LEE ANN JAYKUS
DR. MOHAMMAD KOOHMARAIE
DR. BALA KOTTAPALLI
DR. PATTY LEWANDOWSKI
DR. EVELYNE MBANDI
MS. WENDY McMAHON
DR. ANGELA MELTON-CELSA
DR. HALEY OLIVER
DR. OMAR OYARZABAL
DR. LAURIE POST
MR. JOHN RUBY
MS. ANGELA RUPLE
DR. VIRGINIA SCOTT
DR. SCOTT STILLWELL
DR. ROBERT TAUXE
DR. VALENTINA TRINETTA
DR. ALISA WILMA
DR. FRANCISCO ZAGMUTT

NACMCF EXECUTIVE COMMITTEE:

DR. ARTHUR P. LIANG, CDC Liaison
COL MARGERY HANFELT, Defense Department Liaison
MS. KAREN THOMAS, Advisory Committee Specialist, FSIS

I-N-D-E-X

<u>AGENDA ITEM</u>	<u>PAGE</u>
Opening	5
Dr. Mark Carter	
Welcome	
Capt. Kis Robertson Hale	5
Deputy Assistant Administrator OPHS/FSIS	
Dr. Mickey Parish	9
Director of Senior Science Advisor FDA/CFSAN	
Introduction of Individuals Present	12
Housekeeping Matters	17
Dr. Mark Carter	
Committee Deliberation: Recommendations regarding the effective <i>Salmonella</i> control Strategies for Poultry	19
Dr. Gary Acuff	
Adoption of Report	27
Committee Deliberation: Recommendations regarding the virulence factors and attributes that define foodborne Shiga toxin-producing <i>Escherichia coli</i> (STEC) as severe human pathogens	28
Dr. Carolyn Hovde Bohach	
Adoption of Report	35
Present New Work Charge: Microbiological testing by industry of ready-to-eat foods under FDA's jurisdiction for pathogens (or appropriate indicator organisms): verification of preventive controls	37
Dr. Virginia Scott, FDA	

I-N-D-E-X

<u>AGENDA ITEM</u>	<u>PAGE</u>
Present New Work Charge: The use of water in animal slaughter and processing Dr. William Shaw, FSIS	39
Wrap Up and Adjourn Capt Kis Robertson Hale Dr. Mark Carter	52

1 P-R-O-C-E-E-D-I-N-G-S

2 (8:15 a.m.)

3 DR. CARTER: Thank you. If you don't know
4 who I am by now, I'm Mark Carter. I'm the DFO. I'm
5 an employee of FSIS. I work for the Office of Public
6 Health Science, and next on our agenda, we're going to
7 hear some remarks from FSIS and FDA.

8 And I'm going to introduce my Assistant
9 Administrator, Captain Kis Robertson Hale, and she'll
10 be representing our NACMCF Chair, who is Carmen
11 Rottenberg. As I mentioned before, she can't be here
12 with us today.

13 CAPT. HALE: Good morning, everyone.

14 DR. CARTER: Try pressing the button.

15 CAPT. HALE: Good morning and welcome,
16 everyone. It's great to see everyone, and a lot of
17 work has gone into this. So first off, I want to
18 thank the planners for getting us started off to a
19 great meeting.

20 I'm Kis Robertson Hale. I'm the Deputy
21 Assistant Administrator of the Office of Public Health
22 Science for FSIS. And I'm representing Carmen
23 Rottenberg, our Acting Deputy Under Secretary for Food
24 Safety and the current Chair for NACMCF. She cannot
25 be here today.

1 To my left is Dr. Mickey Parish, who is the
2 Director of Senior Science Advisor Staff at FDA's
3 Center for Food Safety and Nutrition, CFSAN, and he is
4 filling in today for our NACMCF Vice Chair, Dr. Susan
5 Mayne who also could not attend today.

6 So this meeting is our plenary meeting for
7 2018. It's a very important meeting as the Committee
8 is coming together to deliberate on recommendations
9 regarding *Salmonella* control strategies in poultry, as
10 well as virulence factors and attributes that define
11 foodborne Shiga toxin-producing *E. coli* as severe
12 human pathogens from FSIS and FDA, respectively.

13 Our goal today is for NACMCF to adopt final
14 recommendations for FSIS and FDA by the close of this
15 meeting.

16 Our two subcommittees worked very intensely
17 on these projects for the last couple of years, so
18 that we could provide this very useful food safety
19 information to both Agencies. On behalf of USDA Food
20 Safety and Inspection Service, FDA and CDC within the
21 Department of Health and Human Sciences, the National
22 Marine Fisheries Services, U.S. Department of Commerce
23 and Veterinary Service Activity at the U.S. Department
24 of Defense, we thank each of you for lending your
25 expertise to this project, and we especially recognize

1 Subcommittee members and assisting experts for their
2 commitment and hard work that went to the projects.
3 We also commend the entire NACMCF team for their
4 monumental efforts important projects.

5 At FSIS, we work really hard to advance a
6 science-based public health data driven public health
7 agenda. As the public health agency responsible for
8 ensuring the safety of meat, poultry, processed egg
9 products, as well as Siluriformes products, increasing
10 *Salmonella* illnesses is one of our top most
11 priorities.

12 However, *Salmonella* still remains a major
13 public health problem and an important cause of
14 illnesses from FSIS regulated products, and poultry,
15 in particular, remains a commodity that's associated
16 with the largest proportion of *Salmonella* illnesses.

17 So in the Agency, we've taken a number of
18 actions to decrease *Salmonella* illnesses from the
19 products we regulate including poultry. And those
20 actions align to our 5-year strategic plan which is on
21 the web and includes a goal of decreasing illnesses
22 and a goal of modernizing regulations and our
23 inspection procedures based on how we operate as an
24 Agency.

25 Each year we lay out the specific activities

1 we plan to accomplish. We post those on our website,
2 and those represent our annual plans.

3 One way we try to ensure that we are
4 modernizing our policies and inspection systems is by
5 incorporating the best available science into our
6 decisions as an Agency.

7 FSIS is continuing to use science and risk
8 assessments to develop policies and regulations that
9 will protect the public's health by decreasing
10 foodborne illnesses. And to do so, we make sure we
11 have at our fingertips the most current science in our
12 implementing state of the art data analysis and risk
13 assessment.

14 Also to that end, we are also reaching out
15 to our research partners and external advisors to
16 ensure we have the necessary information to help us
17 solve the public health problems that we are regularly
18 confronted with.

19 So looking ahead, controlling *Salmonella*
20 will likely take a multi-pronged approach with a
21 combination of approaches on farm, at the
22 establishment and beyond, and we will continue to work
23 with our partner agencies, researchers and industry,
24 many of whom are here today, to control *Salmonella* in
25 poultry.

1 Likewise, I'm certain that the FDA is
2 looking forward to receiving the Committee's
3 recommendations on virulence factors and attributes
4 that define STEC as severe human pathogens.

5 In conclusion, I again thank everyone who
6 has served on NACMCF and for your work on these
7 projects. You serve an important advisory role, and
8 your contributions really do help us built a better
9 food safety system. Thank so much for your time and
10 your dedication to the food safety and public health,
11 and I really look forward to the discussion here
12 today.

13 Now I'll turn the floor over to Dr. Mickey
14 Parish, the Director of the Senior Science Advisor
15 Staff at CFSAN and our representative for the NACMCF
16 Vice Chair.

17 DR. PARISH: Thank you, Kis. I would like
18 to join you in the comments that you've made today to
19 welcome everyone. Welcome to your Nation's capital.
20 We appreciate your time and effort and your dedication
21 that you're willing to put a not insignificant amount
22 of time for the next 2 years into these efforts.

23 I would like to acknowledge not just FDA and
24 FSIS, but also CDC, DoD, NOAA, for their strong
25 support of NACMCF in the past and continuing strong

1 support of NACMCF in the future, and also the NACMCF
2 Executive Secretariat, Karen, Mark and others who have
3 made this possible. It takes a lot of work and effort
4 to pull together administratively, using Government
5 regulations to make sure that we can meet together as
6 a group of experts.

7 So we have two new charges to address. I
8 think both of them are quite important. Obviously the
9 use of water, of recycled water in meat processing is
10 a critical concern as is the FDA charge on process
11 controls and addressing products and their use in
12 microbiological criteria.

13 So we look forward to your response in 2
14 years, and we look forward to the adoption of two
15 products that were produced in the last cycle.

16 So I would like to recognize Alison O'Brien
17 and Carolyn Hovde, for their work, Gary Acuff and Guy
18 Loneragan for their work on those charges and thank
19 you for that, for what you've done.

20 I would also like to recognize coming up,
21 Peggy Cook and Omar Oyarzabal for the work that
22 they're going to do in leading one of the
23 subcommittees and also Kathy Glass and Laurie Post for
24 their work that they have agreed to do in leading the
25 FDA subcommittee.

1 In addition to Committee members, you'll
2 notice that there will be technical advisors available
3 for use of the subcommittees. FDA has provided a
4 number of technical advisors. It may be possible to
5 bring in other technical advisors for the use from
6 outside, perhaps academia, as needed, and we would
7 encourage you to do that if you reach an impasse where
8 you need some additional information.

9 Please feel free to ask. We're happy to
10 help provide that information as necessary and to try
11 to twist a few arms of our friends in academia or
12 industry to get them to help if necessary.

13 We have a broad community of experts here,
14 academia, industry, federal government, state
15 government, as well as consumer group and we are very
16 happy to have everyone's input.

17 For FDA, I just wanted to point out the
18 importance of preventive controls and potential for
19 product testing and it's impact as a verification
20 tool, remains an incredibly important aspect of FSMA.
21 We wrote the charge with a very specific concern in
22 mind, and we have a number of questions there. We
23 understand that the Subcommittee when they read the
24 charge and they see the questions, may have some
25 additional questions themselves about what was our

1 intent.

2 So with that in mind, Jenny Scott will be
3 representing FDA as the FDA member of the Committee.
4 She'll be on the Subcommittee, and we will have
5 additional FDA personnel available to help answer any
6 questions and provide input.

7 So I served on this committee two cycles ago
8 myself as the FDA member. It was highly memorable
9 experience. That was the DoD charge on micro
10 criteria, had a great time. I learned to love this
11 building. You come down here and spend 2 or 3 days
12 with people that you don't see but every once in a
13 while. The food trucks are wonderful. The food trucks
14 outside here are wonderful. There are good
15 restaurants nearby as well, and you'll learn to have a
16 soft spot in your heart for coming here and working
17 together on this Committee.

18 So thank you again for your efforts and your
19 efforts in the past as well as the efforts you're
20 going to put into this, in the next few years and we
21 look for, as Kis said, to your reports to the
22 Agencies in the future.

23 So with that, I'll turn it back over to
24 Mark, I believe, for continuing with the agenda.

25 DR. CARTER: Thank you, Mickey. Thank you,

1 Kis. All right.

2 Next on the agenda is a roll call. So this
3 is the official part of the meeting. We need everyone
4 to state their name, everyone who's here, to state
5 their name and affiliation, and this is for the
6 record. This goes on the public record for the NACMCF
7 minutes for our meeting. So I will start.

8 I'm Mark Carter, and I'm with FSIS. You'll
9 need to press the button on your microphone when you
10 speak.

11 MS. SCOTT: Good morning. I'm Jenny Scott.
12 I'm with FDA's Center for Food Safety and Applied
13 Nutrition.

14 DR. DIEZ: Hi, Francisco Diez, Center for
15 Food Safety, University of Georgia.

16 DR. MELTON-CELSA: Good morning. I'm Angela
17 Melton-Celsa. I'm with Uniformed Services University.

18 MS. McMAHON: Wendy McMahon with Silliker.

19 DR. EIFERT: Joe Eifert, Virginia Tech, Food
20 Science and Technology.

21 DR. ZAGMUTT: Francisco Zagmutt, Epix
22 Analytics in Fort Collins, Colorado.

23 DR. LEWANDOWSKI: Patty Lewandowski, Florida
24 Department of Health.

25 DR. DICKSON: Jim Dickson, Iowa State

1 University.

2 DR. TAUXE: Rob Tauxe, Centers for Disease
3 Control and Prevention.

4 DR. MBANDI: Evelyne Mbandi, FSIS.

5 DR. LIANG: Art Liang -- oh, excuse me.

6 CAPT. HALE: Kis Robertson Hale, FSIS.

7 DR. PARISH: Yeah, Mickey Parish, FDA.

8 DR. LIANG: Art Liang, CDC. I'm a member of
9 the Executive Committee.

10 COL HANFELT: Margery Hanfelt, Department of
11 Defense, Veterinary Services.

12 DR. WILMA: Alisa Wilma, Department of
13 Defense, Veterinary Services.

14 DR. ELLIOTT: Phil Elliott, Kellogg Company.

15 DR. OLIVER: Haley Oliver, Food Science,
16 Purdue University.

17 MS. DAVIS: De Ann Davis, Church Brothers
18 Farms.

19 DR. ACUFF: Gary Acuff, Texas A&M
20 University.

21 DR. HOVDE: Hi, everyone. Carolyn Hovde,
22 University of Idaho.

23 DR. COOK: Petty Cook, Tristrata Group.

24 MR. ASMUS: Aaron Asmus, Hormel Foods.

25 DR. TRINETTA: Valentina Trinetta, Kansas

1 State University.

2 DR. KOOHMARAIE: Mohammad Koohmaraie, IEH
3 Laboratories.

4 MS. COFFMAN: Vanessa Coffman, The Keep
5 Antibiotics Working Coalition.

6 MR. RUBY: John Ruby, Church & Dwight,
7 Animal Production.

8 DR. KOTTAPALLI: Bala Kottapalli, ConAgra
9 Brands.

10 DR. PETRAN: I'm Ruth Petran with EcoLab.

11 DR. STILLWELL: Scott Stillwell, Tyson
12 Foods.

13 MS. RUPLE: Angela Ruple, NOAA Fisheries.

14 DR. JAYKUS: Lee-Ann Jaykus, North Carolina
15 State University.

16 DR. OYARZABAL: Omar Oyarzabal, University
17 of Vermont.

18 DR. GLASS: Kathy Glass, University of
19 Wisconsin-Madison.

20 DR. POST: Laurie Post, Deibel Laboratories.

21 DR. CARTER: Let's continue with the next
22 group behind.

23 MR. JONES: William Jones, FDA.

24 MR. DAVIDSON: Gordon Davidson, FDA.

25 MS. ZERKE: Maria Zerke, FDA.

1 MS. SILVA: -- Silva, FDA.

2 MS. HANNON: Bertha Hannon, FDA.

3 UNIDENTIFIED SPEAKER: Sorry. I'm just a
4 member of the public. I didn't know I was supposed to
5 sit over there.

6 DR. CARTER: You don't have to sit anywhere
7 special, but we do need to know -- we need to know
8 your name and affiliation, please.

9 MR. HALL: Sorry. Mark Hall, USDA.

10 JAMES: James --

11 MS. HARKLESS: Rita Harkless, Perdue Foods.

12 DR. CARTER: And over here?

13 MR. PARSONS: Grant Parsons -- Perdue.

14 DOLLY: Dolly Abu --

15 MR. WHEELHOUSE: Carl Wheelhouse, Natural
16 Technologies.

17 DR. CARTER: Okay.

18 MR. ALLARD: Marc Allard, FDA.

19 MS. WALKER: Kimberly Walker, American
20 Society for Microbiology.

21 MR. FLOOD: Lee Flood, R&S --

22 KATIE: Katie -- American Native --

23 MS. COOK: Shannon Cook, DGMA.

24 MS. DELTA: Alma Delta, TMA.

25 UNIDENTIFIED SPEAKER: I'm (Indiscernible).

1 DR. CARTER: I'm sorry. What's your
2 affiliation?

3 UNIDENTIFIED SPEAKER: I have no
4 affiliation.

5 DR. CARTER: Okay. Just public?

6 UNIDENTIFIED SPEAKER: Yes.

7 DR. PETERSON: Ashley Peterson, National
8 Chicken Council.

9 MS. MASTERS: Barb Masters, Keystone Foods.

10 DR. BOOREN: Betsy Booren, OFW Law.

11 MR. BOWERS: John Bowers, FDA.

12 DR. FENG: Peter Feng, FDA.

13 DR. CARTER: Is there anyone who has not yet
14 introduced themselves?

15 (No response.)

16 DR. CARTER: Okay. Thank you. So next,
17 before we begin the program in earnest, I have a few
18 business announcements. The four documents we're
19 going to discuss today are all available on the FSIS
20 website. They're also available in hard copies. If
21 you are a member of the Committee, you should have
22 copies of all the documents at your station. So the
23 reports are the thick ones that are stapled together
24 and the charges I believe are in the notebooks. And
25 if you are not a Committee member, there are hard

1 copies that are available outside. If you didn't pick
2 them up yet, they're out on the countertop on your way
3 in, and you may want to read along as the reports are
4 reviewed.

5 Okay. As I mentioned earlier, the current
6 NACMCF Charter expires February 3, 2019. The Charter
7 is also available for review on the FSIS website.
8 Very soon, we'll be begin the process to renew the
9 charter so that it renews prior to expiration.

10 This is a public meeting, and so we have
11 time for public comments. We look forward to input
12 from the public and please note that we are soliciting
13 only comments related to the *Salmonella* control
14 strategies in poultry and the STEC lab reports that
15 we're discussing today. We're not asking for comments
16 beyond the scope of the NACMCF draft reports being
17 discussed today.

18 For guests wishing to make public comment
19 please come to the microphone, repeat your name and
20 affiliation for the record, before making a comment
21 and please limit your comments to 5 minutes.

22 Lastly, the Subcommittee chairs, members and
23 assisting experts worked extremely hard on these
24 projects, everyone really stepped up to the plate to
25 make it happen. I want to say many thanks for your

1 efforts on these reports, and especially to the
2 assisting experts.

3 So next on our agenda is Dr. Gary Acuff who
4 was our *Salmonella* Subcommittee co-chair who will
5 present the draft document on Controlling *Salmonella*
6 in Poultry for adoption. He will go through the
7 report, and then we will take brief comments. If you
8 have comments that you need to make during the report,
9 Committee members can contribute comments as we go
10 along. Again we're not going to change the report,
11 but we'll just submit a report with your comments as
12 an addition. So if at any given point in the report
13 review, you feel you obliged to make a comment, please
14 interrupt and you may make your comments. Dr. Acuff.

15 DR. ACUFF: Thank you, Mark. So our
16 Subcommittee was chaired by Dr. Guy Loneragan and I
17 was co-chair. Guy could not be here today. So I
18 agreed to run through the report.

19 We have received comments from most of the
20 Subcommittee members on the final draft, and we've
21 also received comments from new Committee members,
22 Drs. Eifert, Zagmutt, Scott and Glass. So we have all
23 those comments also.

24 So our intent at this point is to make final
25 changes to the document but they're for the most part

1 minor and the report will probably stand as it is at
2 this point.

3 So going through what we have so far, the
4 report is in response to the questions posed by the
5 USDA, FSIS, regarding poultry, *Salmonella* in poultry.
6 We had six questions that were provided to the
7 Subcommittee, and the organization of the document is
8 -- we have an executive summary where we provided very
9 brief responses to the questions, and then were not
10 asked for a recommendations section, but we did that
11 anyway because we couldn't help ourselves.

12 So we provided our recommendations and then
13 we did an introduction, talked about all of the
14 questions in detail, and then you can see in Section
15 4, we answered each question in detail with quite an
16 extensive discussion.

17 So I need to go through -- we need to go
18 through each page and ask if there are comments. Is
19 that -- if I turned on the microphone, you could to
20 respond to me.

21 (Laughter.)

22 DR. ACUFF: All right. So if anyone has
23 comments, then I think what we'll do is go through the
24 document a page at a time and if you have anything you
25 want to address, then speak up, and we'll make note.

1 Is that correct?

2 Okay. So starting with -- well, let's move
3 past the executive summary to the recommendations. So
4 that will be page 5. Any comments on page 5? On page
5 6, those are all recommendations.

6 (No response.)

7 DR. ACUFF: All right. So the then
8 introduction begins on page 7. The specific charge
9 was on page 8. And then discussion of our first
10 answering the charge on page 9. We basically broke
11 question up into question 1 and 2, and then questions
12 3, 4 and 5, we broke into working groups, and then we
13 all -- the Subcommittee all came back together to
14 answer question 6.

15 All right. So responses to each of the
16 questions begins on page 10. The first question was,
17 what criteria defines *Salmonella* that are highly
18 virulent to humans? Are markers serotype specific?
19 And then there was a subquestion, what tools are
20 available for continuing to identify the most virulent
21 foodborne salmonellae?

22 So any comments, questions about page 10,
23 page 11, page 12 or 13? If anyone behind has a
24 question, just speak up and I'll stop. Page 14.

25 (No response.)

1 DR. ACUFF: All right. So page 15, question
2 2 was, where does *Salmonella* reside inside and on the
3 surface of poultry and how do those populations of
4 bacteria contribute to food contamination? The sub
5 questions were, discuss locations, persistence and
6 resistance to interventions. And then discuss the
7 latest information on the ecology of *Salmonella* within
8 or on poultry regarding the gut, cloaca, bone marrow,
9 the heart, skin follicles/skin surfaces, lymphatic
10 system, immune evasion and other. Discuss strategies
11 to mitigate risk factors at these locations.

12 So that answer then is on the rest of page
13 15, 16. Comments on page 17, page 18, page 19, 20,
14 page 21, 22, page 23, 24, page 25? Dr. Scott.

15 MS. SCOTT: I know we've submitted comments,
16 but I just want to point out that this document will
17 be read by people who are not familiar with FSIS'
18 performance standards, testing procedures and terms
19 like set base sampling and moving window need to be
20 explained in this document.

21 DR. ACUFF: Correct. Yes. Yeah, we will --
22 we've developed some text to address that. So we'll
23 definitely cover that in the final document. Thank
24 you.

25 Okay. Finishing, 25, 26.

1 (No response.)

2 DR. ACUFF: Question 3 was in two parts.
3 Question 3, Part A was, would removing flocks of
4 highly *Salmonella*-contaminated birds entering the
5 slaughter plant reduce foodborne illnesses in humans?
6 What are important considerations to arriving at a
7 threshold level, looking at prevalence or load, of
8 *Salmonella* associated with incoming birds that would
9 necessitate additional control steps in the food
10 safety system or HACCP plan?

11 Our answer to that is on page 27. Any
12 comments there?

13 (No response.)

14 DR. ACUFF: Page 28, Part B of that question
15 was, what are they key considerations or steps for an
16 alternative processing scenario if the threshold level
17 is exceeded?

18 (No response.)

19 DR. ACUFF: And then Question 4 on page 29,
20 what should raw poultry establishments consider when
21 determining the appropriate level of *Salmonella*, or
22 threshold, that would necessitate additional control
23 steps in the food safety system or HACCP plan?

24 And then the Committee's response is there
25 on page 29. Any comments on page 29 or 30, page 31,

1 page 32?

2 (No response.)

3 DR. ACUFF: On page 33, we have question 5.
4 As informed by questions 3 and 4, what methods are
5 best suited to measure pathogen levels on animals and
6 in product more rapidly than current tests?

7 That response is on the bottom of page 33.

8 Any comments or questions on 33, 34?

9 (No response.)

10 DR. ACUFF: Also there is a Part B to
11 question 5 on page 35. That is, what is a sampling
12 scenario that would enable an establishment to test
13 incoming birds and product for a threshold *Salmonella*
14 level and have a result in a timely manner so that
15 processing can proceed as appropriate?

16 Our response is there on page 35. Any
17 comments? Page 36. Comments on page 37?

18 (No response.)

19 DR. ACUFF: All right. Question 6, the last
20 question, considering the farm-to-the-table continuum
21 for poultry, what are the top three focus points,
22 control measures or best practices, that would be
23 compatible with industry-wide practices, which could
24 be addressed or implemented to achieve the highest rte
25 of reduction of *Salmonella* with regard to both

1 foodborne illnesses and on product?

2 So the Subcommittee actually in typical
3 fashion, instead of identifying three focus points, we
4 identified four answers, because we couldn't limit
5 ourselves to three. So you see the four answers
6 there, and they continue on through page 37. Any
7 comment on page 38, page 39 and page 41?

8 DR. COFFMAN: Hi, this is Vanessa Coffman.
9 I have a question on page 41, and maybe this is a
10 question for Karen and the group. So we're talking
11 about consumers and what we're going to do to address
12 the consumer role in food safety. And I'm wondering
13 how we're going to communicate these documents to the
14 public at large, you know, nobody going to go from the
15 general community into the general purpose section to
16 read the full document. I'm not sure as to what we're
17 going to do to communicate to the consumer.

18 DR. ACUFF: So I know it will be posted on
19 the FSIS webpage and Federal Food Protection. I
20 assume that also food safety organizations will pick
21 up that document and help us summarize it but, Evelyn,
22 maybe you can respond to that.

23 DR. MBANDI: This is Evelyn Mbandi, FSIS.
24 That's correct. We're going to post the report on the
25 web. We will have a constituent update announcing the

1 availability of this document and hopefully more
2 people will have access to the document in addition to
3 publishing in JFP.

4 DR. COFFMAN: Okay. So that constituent
5 update is a press release?

6 DR. MBANDI: Yes, that is correct. We
7 create a press release.

8 DR. COFFMAN: Okay.

9 DR. ACUFF: All right. So we have -- in
10 addition to that, we have a three pages, page 53, of
11 references. I'm sure we all read those carefully.
12 Actually the Subcommittee has. But any comments on
13 the references and then that will complete the
14 document?

15 (No response.)

16 DR. ACUFF: All right. So speaking on
17 behalf of Dr. Loneragan, the Chair, we appreciate all
18 of the comments that we did receive. There were some
19 very thoughtful and helpful comments. So we will
20 address those. Most of them were minor, just some
21 things that we need to elaborate on, but we will
22 address all of those and take care of in the final
23 document.

24 DR. CARTER: Thank you, Dr. Acuff.

25 I'll receive the final report from the

1 Subcommittee. We will post this on the FSIS website
2 and submit it for publication by the journal of food
3 protection.

4 The Committee would now like to invite
5 public comments on the *Salmonella* control. Please be
6 reminded that we're soliciting comments only related
7 to this project and the document that Dr. Acuff just
8 discussed.

9 Again, if you wish to make a public comment,
10 please come to the microphone and repeat your name and
11 affiliation for the record before making a comment.

12 Are there any public comments? Going once.
13 Going twice.

14 (No response.)

15 DR. CARTER: Very well. We'd like to move
16 to adopt this document. And do we have a motion from
17 the Committee members to adopt this as final with the
18 changes as described?

19 DR. KOOHMARAIE: I'll make a motion.

20 DR. OYARZABAL: Second.

21 DR. CARTER: Very well. That is
22 Dr. Koohmaraie's motion to be approved. And second
23 from Omar.

24 I would propose to approve this as unanimous
25 by acclamation. Is there any dissent? Any dissent

1 among the Committee?

2 (No response.)

3 DR. CARTER: Then it's approved unanimously.

4 Thank you.

5 And thank you, Dr. Acuff, for your work on
6 the Subcommittee. It is much appreciated.

7 Congratulations on adoption of the document.

8 Next on our agenda is Dr. Carolyn Hovde
9 Bahach. Our FDA Subcommittee Co-Chair will present
10 for adoption the draft document on virulence factors
11 and attributes that define STEC as severe human
12 pathogens. She will go through the report, and we'll
13 take comments as we go along.

14 DR. HOVDE: Thank you, Mark, and thank you
15 to everyone who worked on this document. I think we
16 can feel very proud of what we've created. This
17 document is 163 pages long, and so we're not going to
18 go through it exactly page by page but more in groups
19 of pages.

20 The Chair of this group, of course, was Dr.
21 Alison O'Brien, and I was Co-Chair.

22 Everyone on the Committee has read and
23 submitted typographical changes and very good, what I
24 would call minor changes that improve the clarity of
25 the document.

1 Just as the previous document, we start with
2 an executive summary, and that goes from page 1
3 through page 4.

4 If there are any comments on the executive
5 summary, please make them now.

6 (No response.)

7 DR. HOVDE: There's also on pages 5 through
8 9, the executive summary of the charge, and what can
9 be found in these pages are the specific questions
10 that we addressed and in bold are the chapters that
11 address each of the charges, and I think for clarity,
12 that will be easy to follow. So that's pages 1
13 through or through page 9. Comments?

14 (No response.)

15 DR. HOVDE: We then have an overview and
16 introduction, the steps of pathogenesis, the
17 prevention detection and surveillance, and then we
18 begin with chapter 1 on page 14, clinical and
19 epidemiologic features of STEC. In that chapter, we
20 covered descriptive epidemiology, surveillance of
21 infections, incidents of serotypes, clinical features
22 and we have incorporated summaries throughout the
23 document. The first summary is on page 16. Comments
24 thus far?

25 (No response.)

1 DR. HOVDE: We then talked about the burden
2 of health, I'm sorry, the burden of illness,
3 international burden, and trends and incidence,
4 change in incidence, attributes of health burden and
5 food sources. And there's a summary of that on page
6 24. Yes, comment.

7 DR. GLASS: Kathy Glass, UW-Madison. One
8 thing with the C.4 attribution by case-control
9 studies, I think it would be useful if we could
10 include where the failures occurred. For example,
11 they have sliced delicatessen meat as being a risk
12 factor with *E. coli* 0157, to identify whether or not
13 this was an occurrence that deli recontamination is a
14 risk factor versus failures in cooking as a risk
15 factor would be I think very useful to put in there.

16 DR. HOVDE: Where is this?

17 DR. GLASS: With C.4 from line --

18 DR. HOVDE: 507?

19 DR. GLASS: -- 509 specifically --

20 DR. HOVDE: 509.

21 Dr. GLASS: -- and 507.

22 DR. HOVDE: And would that distinction be in
23 the references?

24 UNIDENTIFIED SPEAKER: It should be
25 referenced.

1 DR. HOVDE: Yeah, the reference is at the
2 end of that line. I guess I'm asking back to you.
3 But your suggestion is to have specific language in
4 the sentence. Is that correct?

5 DR. GLASS: Say that again?

6 DR. HOVDE: Is your suggestion to change the
7 sentence specifically to add your comment --

8 DR. GLASS: To clarify -- yes.

9 DR. HOVDE: -- in the sentence, not just the
10 fact that the references could lead someone to that
11 understanding.

12 DR. GLASS: Yes, to clarify where the
13 failure occurred.

14 DR. HOVDE: Very good. Further comments
15 about that sentence?

16 DR. KOOHMARAIE: Well, most of --

17 DR. CARTER: Please state your name and
18 affiliation.

19 DR. KOOHMARAIE: Mohammad Koohmaraie, IEH
20 Laboratories, and I was on this Subcommittee. I was
21 just making a comment that the comment that was just
22 made with regard to --

23 DR. TAUXE: This is Bob Tauxe. The comment
24 on the comment, we'd have to go back and look at the
25 three references that are mentioned here, 93, 194 and

1 258, but small case control studies comparing
2 exposures of patients in population controls, if I
3 were talking to a patient about what they ate, how
4 would they know whether the sausage or whatever was
5 undercooked or under processed? They would just know
6 they ate processed meat. So that essentially may not
7 have been available to the study. We can go back and
8 look.

9 DR. HOVDE: Other comments about this?

10 (No response.)

11 DR. HOVDE: Okay. Going forward, prevalence
12 on page 25, comments of STEC in cattle, we went
13 through virulence and putative virulence genes of STEC
14 in cattle, prevalence of STEC in food, prevalence in
15 produce, prevalence in beef and dairy products, and
16 that we have an overall chapter summary on page 29.
17 Comments here?

18 (No response.)

19 DR. HOVDE: Chapter 2, we talked about
20 virulence profiles and pathogenesis of STEC, talking
21 about serotypes associated with human illness,
22 virulence factors that include colonization factors,
23 all the way to summarize that area on page 35.
24 Comments?

25 (No response.)

1 DR. HOVDE: We then talked about Shiga
2 toxin, phage coding of the toxin, summarized that on
3 page 41; talked about other toxins, acid tolerance,
4 approaches to predicting the capacity of STEC to cause
5 severe illness, models to predict virulence,
6 summarized that and animal models and summarized that.
7 The overall chapter 2 summary is on page 47. Comments
8 on these?

9 (No response.)

10 DR. HOVDE: Chapter 3 discusses methods to
11 detect and characterize STEC, starting at the bottom
12 of page 47. We did an overview of the protocols used
13 by USDA FSIS, FDA or in clinical settings. We talked
14 about advantages and disadvantages of these methods.
15 On page 55, we did an overview of protocols currently
16 used in the food industry for the detection of STEC,
17 detection of virulence genes and serotype, the
18 advantages and limitations, new and developing high
19 throughput methods on page 61, limitation procedures,
20 PCR, biosensor, microarray, high-throughput methods,
21 genomic clusters and lineages, list prediction, DNA
22 sequencing, transcriptomics and preteomics. And we
23 summarized this chapter on page 70 and 71.

24 Comments on this section please?

25 (No response.)

1 DR. HOVDE: We have Chapter 4, gaps and
2 recommendations, on page 72, 73 through 78, and tables
3 and figures that go through page 99.

4 Comments on this material?

5 (No response.)

6 DR. HOVDE: We've included an appendix with
7 case studies on page 100. On page 106, an appendix
8 that lists the acronyms that were used.

9 Comments on those appendices?

10 (No response.)

11 DR. HOVDE: We've come to the references
12 that start on page 114 to the end of the document.

13 Comments on the references?

14 (No response.)

15 DR. CARTER: Thank you, Dr. Hovde. If there
16 are no further comments for Dr. Hovde, I'd like to
17 personally apologize for a break of protocol. The
18 last time I was in front of you, I usurped the floor
19 from the Committee Chair, which is represented by
20 Captain Kis Robertson Hale, and she should be the one
21 who is actually administering the approval process.
22 Would you like me to do it for the second one?

23 CAPT. HALE: No, I can do it, but -- thank
24 you. It's no big deal.

25 So we'll see if there's any public comments

1 before we move.

2 (No response.)

3 CAPT. HALE: All right. Hearing none, we'd
4 like to move to adopt this document. Can I get a
5 motion from the Committee to adopt this document as
6 final?

7 DR. ACUFF: Motion to approve.

8 CAPT. HALE: Do I have a second?

9 DR. DIEZ-GONZALEZ: Second.

10 DR. CARTER: Will you please state your name
11 for the record?

12 CAPT. HALE: Can you state your name for the
13 record? State your name for the record.

14 DR. ACUFF: Gary Acuff, Texas A&M.

15 DR. DIEZ-GONZALEZ: Francisco Diez-Gonzalez,
16 University of Georgia.

17 CAPT. HALE: Thank you. So the vote was
18 unanimous acceptance, approval?

19 (No response.)

20 CAPT. HALE: Okay. Thank you.

21 Thank you, Carolyn. We really appreciate
22 the work that the Subcommittee did on this. So great
23 job. So what are our next steps then for this?

24 DR. CARTER: So the Subcommittee will
25 incorporate the comments into the final report, and

1 then pass it up to the NACMCF. And then upon receipt
2 of the final report, we will list it on the FSIS
3 website and submit it for publication. Jenny.

4 MS. SCOTT: Just a comment. I want to thank
5 the Committee for an excellent report and the
6 timeliness of it. The CODEX Committee on food hygiene
7 is about to move forward in taking that new work under
8 control of STEC, and this information will be very
9 helpful as we develop our project documents and move
10 forward. Thank you.

11 DR. CARTER: Very good. Are there any
12 public comments on the reports that were presented
13 today?

14 (No response.)

15 DR. CARTER: So I need to see what time it
16 is. Our agenda has us going through fairly late in
17 the day but -- that maybe we would just move on, since
18 everybody's here, and then maybe we'll be able --

19 CAPT. HALE: Do you want to move to
20 presenting the charges then? Is that the plan?

21 DR. CARTER: Okay.

22 CAPT. HALE: Okay. So let's do that. Mark,
23 you want to tee that up.

24 DR. CARTER: Thank you, Kis. FSIS has
25 prepared charges for the new NACMCF, and our next

1 agenda item is presentation of the new charges.

2 The FDA charges will be presented first by
3 Dr. Jenny Scott.

4 MS. SCOTT: Thank you, and for the record,
5 there's no doctor.

6 I'm going to present the charge on
7 microbiological testing by industry of ready-to-eat
8 foods under FDA's jurisdiction for pathogens, or
9 appropriate indicator organisms, as a verification of
10 preventive controls.

11 In 2015, FDA published a final rule under
12 FSMA, the FDA Food Safety Modernization Act, on
13 preventive controls for human food. Facilities are
14 required to conduct hazard analysis and implement of
15 any controls for hazards identified as requiring them.
16 These provision controls must be monitored and
17 verified and corrective actions taken when they're not
18 properly implemented.

19 Verification activities for preventive
20 controls from microbial hazards include product
21 testing for a pathogen or appropriate indicator
22 organism as appropriate to the food the facility and
23 the nature of the control of the facility's food
24 safety system under a flexibility clause. So industry
25 asked us to put flexibility in our approach and we did

1 so.

2 Moreover because of the flexibility that FDA
3 provided in the rule, there's a lack of clarity by
4 industry and by FDA investigators as to when such
5 testing is appropriate.

6 So FDA is seeking advice from NACMCF on the
7 utility and necessity of industry testing of ready-to-
8 eat food for pathogens, or indicator organisms, and
9 the criteria the industry could apply in determining
10 what, if any, microbial testing is appropriate for
11 verifying pathogen control for ready-to-eat foods
12 produced by a facility.

13 Such advice should include specifics on
14 tests for microorganism or microorganisms, the
15 sampling plan that should be used, the type of test,
16 that is presence or absence or enumeration, the
17 frequency of such testing, interpretation of results
18 and actions to take when such testing indicates a loss
19 of control.

20 We're also requesting advice from NACMCF on
21 the use by industry of enzymatic indicators of
22 application of heat-based processes, such as alkaline
23 phosphatase for pasteurization of milk, and whether
24 there are situations where verification testing of
25 products by industry would not be necessary if there's

1 evidence that appropriate treatment was applied.

2 The charge includes a list of food
3 categories of concern, and asks specific questions,
4 for example, about the principles and criteria a
5 company should apply in selecting the test
6 microorganism and frequency testing and the results
7 that would indicate a loss of process control.

8 Are there any questions?

9 (No response.)

10 DR. CARTER: Thank you, Jenny.

11 The Subcommittee members will have plenty of
12 opportunity for in depth discussion of the charge.

13 Next, we will hear from Bill Shaw who will
14 present the FSIS charge. Do you have slides?

15 DR. SHAW: Yes. Okay. So Jenny is a lot
16 quicker than I am. I'm really excited to talk about
17 this charge, and I hope that those of the Subcommittee
18 will find it enjoyable. You know, it's not the
19 typical FSIS charge of late, yet it is a totally an
20 inclusive USDA charge.

21 This charge is about food safety,
22 modernization and new technology, which are the core
23 focuses of FSIS right now, but it also includes
24 agricultural conservation, protection of the
25 environment, sustainability and some intentional

1 prerequisites for flexibility.

2

3 So a charge like this has a lot of moving
4 parts, and I hope that I can give you some of the
5 contacts and ideas that you will then hone into and
6 focus on over the next couple of days. In giving you
7 some thoughts on, you know, options of current water
8 use, future water use concerns, Agency actions that we
9 could potentially take, and then, you know,
10 appropriate charges --

11 And, of course, my staff and I will be
12 around this week, and we'll be here to answer
13 questions and help out as we go along.

14 So when it comes to water, we tend to take
15 it for granted in all aspects of our lives including
16 food processing. It's just always there. We've come
17 to NACMCF over the years about pathogens,
18 interventions, passive, validation and the list goes
19 on, and now it's water.

20 The various regulations around water within
21 the FSIS regulatory structure haven't really been
22 updated since the 1990s. Our policies may be leading
23 to more water usage than is necessary in this current
24 time.

25 We would like you to help us evaluate that

1 and give us advice on the technological improvement
2 available to form our policies around water.

3 This is just a look at water consumption,
4 and you see the black pieces of pie are, you know,
5 what we consider domestic and commercial water by
6 usage, not used in processing. And although it's not
7 the largest usage of water within, you know, the
8 consumption in the United States, it's still sizable
9 at 8 percent of the total water consumption used for
10 this purpose. So it's something that can have
11 benefits if we look at usage. There's an opportunity
12 there.

13 Regardless of where you are on the climate
14 change situation, there's some trends in weather that
15 are showing impact from the availability of clean and
16 inexpensive water. Water is becoming more expensive.

17 I personally was sort of brought to this
18 issue a few years ago in what many call the mini
19 dustbowl. So a few years ago, there was a pretty wide
20 drought in the area just east of where the original
21 dustbowl was. And being in my position at FSIS,
22 looking at new technologies and regulatory waivers,
23 and that's sort of what my staff manages, a number of
24 establishments came to us from that region sort of
25 saying, okay, we may have to look at some alternatives

1 to water reconditioning or getting water or what's
2 open to us? We see that your regs and your policies,
3 you know, may be difficult for us.

4 And ultimately those establishments at that
5 time, you know, with the economic pressures, chose to
6 reduce production dates, rather than implement
7 additional technology.

8 But that was at that time. Industry has
9 continued to talk about this area, and if we have
10 another one, I don't think that would be their choice
11 again based on the things that we've talked about.
12 And at that time, you know, I'm a food microbiologist.
13 So I really hadn't really thought about largely, you
14 know, water treatment systems and all of that sort of
15 thing, but since then, we, within our staff, we've
16 started to educate ourselves.

17 And a tour that the Subcommittee will take
18 later to DC waters is one that I took my staff on, and
19 I think you'll find it really interesting. And we've
20 learned a lot and I think it's time for us then, you
21 know, to ask you for your thoughts.

22 Okay. So this next one, I know this sort of
23 looks at the last couple of years when we've had some
24 drought issues. And if you take nothing from these
25 slides, but look at the red and the orange and the

1 brown, those are areas, in 2012 and 2014, where there
2 were water drought areas that affected the United
3 States. If you look at those areas of the country,
4 they're where our plants are for FSIS. They're where
5 we are at. And so it just further shows that water is
6 something you need to start thinking about if we
7 haven't thought about it before.

8 You know, there are potential actions that
9 our Agency can take. I believe there are
10 opportunities for FSIS to start now in thinking about
11 coming innovations in food processing when it comes to
12 water and have the knowledge and regulatory
13 infrastructure ready to go.

14 I think NACMCF, as in the past, has the
15 technical expertise to assist us in preparing for
16 these innovations, many of which are happening around
17 the world and I believe economic pressures as well as
18 consumer pressures will bring them to the United
19 States.

20 You'll have a speaker later from the
21 industry who will speak to that in particular, and
22 what the challenges are to them and what they're
23 thinking about.

24 So getting to the charge itself, we're
25 requesting guidance from NACMCF to address

1 alternatives to current water usage, whether it adds
2 information about practices, that industry can take,
3 that can help us inform guidance that we provide to
4 industry and it could potentially inform us on some
5 rulemaking ideas.

6 I draw your attention in particular to our
7 sanitation regs, and this Subcommittee I'm sure will
8 spend a lot of time thinking about 416.2, and
9 especially 2(g)(4) which has a very interesting
10 wording in there that, you know, technology today
11 might not make that necessary anymore. And so I hope
12 the group will talk in depth about that.

13 So getting to the questions, and we have
14 plenty of questions. And it shows how water impacts
15 everything that has to do with food processing in one
16 way or the other.

17 So our first question really centers around
18 what are the current water usage practices for
19 slaughterhouses and processors? Where can water be
20 conserved? And, what are some alternative water
21 sources? And that gets into reconditioning and
22 treatment and those various technologies.

23 And then question 2, what are available
24 technological strategies for water? How can you
25 recycle by reclaiming, reconditioning and reusing?

1 I had this weird pipedream that this sort of
2 led to this charge is that is a full closed water
3 system reasonable as an ultimate goal? Can a large
4 slaughter plant be just off the water grid basically?
5 And so is that possible?

6 There are current strategies that many
7 establishments use about drainage and collection of
8 used water, physical filtration, grease traps, HACCP
9 storage and sedimentation, chlorine treatments, but
10 then there are newer technologies that get into the
11 world of reverse osmosis, you know, nanofiltration,
12 ultrafiltration, activated carbon, advanced oxidation.
13 We've got chemical coagulation and electrocoagulation
14 to deal with blood. Constructed wetlands, often we
15 refer to them as lagoons, that are aerobic and
16 anaerobic lagoons in succession. We've got gamma
17 radiation or UV light. So there are lots of options
18 that could potentially impact food processing.

19 Question 3, what are the common contaminants
20 of concern in water? So what are the metrics we can
21 use to determine if these technologies in number 2 are
22 comparable to typical potable water sources today?
23 What are the metrics we need to be concerned about
24 when evaluating these treatment programs?

25 And one of our biggest regulatory hurdles,

1 and I want the Subcommittee to especially spend some
2 time looking again at that 416.2(g)(4), because it has
3 in there, you know, provisions for using reconditioned
4 water but then there's that what we call the rinse
5 requirement. And so if these newer technologies can
6 really take us back, is that necessary any more? In
7 some of these systems, maybe the rinse isn't necessary
8 and we can go back and sort of foster industry in
9 removing these directions because they don't still
10 have to have those rinses again. So think about that.

11 And then question 4, how do residual
12 contaminants in establishment water affect high
13 quality and safety? So this moves to sort of like are
14 there and whether this is from reconditioned systems
15 or water that's coming into establishments today,
16 based on, you know, metrics and requirements of water,
17 can there be contaminants left that can impact the
18 uses of that water? The sort of easiest example is
19 could metal ions or various contaminants impact the
20 effectiveness of antimicrobial interventions? Is that
21 possible? And so this question sort of wraps around
22 that area.

23 Question 5, what are the best ways to assure
24 and/or monitor quality and safety of alternative
25 source water in FSIS regulated establishments? So if

1 we decide that this group of certain water treatment
2 systems are possible, how do we monitor that, whether
3 it's industry, whether it's us? What are the
4 acceptable monitoring practices? Is there testing
5 involved? What should we test for? Phosphorous,
6 total nitrogen, organic carbon, metals such as lead.
7 What should we be concerned about? And then what
8 would be the frequency? So that's sort of what
9 question 5 gets at.

10 Then question 6, so we moved in a little
11 different direction with 6. Are there special
12 considerations for foods that are produced entirely
13 within water? We now have a whole new regulatory
14 structure of Siluriformes fish, and so we didn't think
15 we could ask a water charge without sort of addressing
16 the considerations in that way for us.

17 And then question 7, flooding or runoff can
18 contaminate animals and sources with human sewage and
19 farm waste. What precautions should establishments
20 take? DC water which when we take the trip, has an
21 extensive canal system to deal with overflow. I hope
22 that you pay particular attention to that and see how
23 they work that system to take into account any sort of
24 flooding.

25 And then also think about, so when a

1 municipal water source has a flooding occurrence or
2 has an overflow, a backflow, they often, you know, put
3 out a boil water recommendation. Sometimes those are
4 precautionary when you talk to them, but how should
5 establishments react to that? How should we as an
6 Agency react to that?

7 And then question 8, finally, we get to
8 water replacement. So as many of you know, our
9 sanitation requirements are quite extensive, our
10 regulatory requirements, and this results in often
11 overnight sanitation shifts that use lots of water.
12 And are there alternative procedures that can use
13 less?

14 We know that there are places around the
15 world that have alternate methods, and so what are
16 those and how can we potentially incorporate them into
17 our regulatory structure, into our guidance, into our
18 food processing systems?

19 So that's it in a nutshell, all about water.
20 I know you're used to having us give you things about
21 pathogens and various things, but something a little
22 different this time. Any questions?

23 DR. HOVDE: I have a question. This charge
24 is exclusively towards slaughter processing plants,
25 correct? Not of vegetable, other kinds of food,

1 activities?

2 DR. SHAW: No, and we did this on purpose.
3 This is -- in the title of it we say water in animal
4 slaughter and processing, because if you sort of
5 delves directly into the regulatory structure of FSIS,
6 and FDA has, assuming things in the pipeline, and
7 they're working in this area on their sort of
8 regulatory structure, and we don't want to impede on
9 that. We don't want overlap that. We really want to
10 focus on FSIS regulated slaughter plants and
11 processing facilities, yes.

12 DR. HOVDE: Great. That sounds like a very
13 easy charge. That zeros it right down.

14 DR. SHAW: I'm sure it does.

15 MS. SCOTT: Well, I just want to follow up
16 on Carolyn's question. When you get to the fish, you
17 talk about fish growing in water, but is the charge to
18 the slaughtering of the fish that had been run in
19 water or are you actually asking people to look at the
20 growing waters for the fish?

21 DR. SHAW: Right. When it comes to fish,
22 yes, the growing waters because we were given
23 authority over that. So, yes, it's the ponds and then
24 also water in the slaughter facility.

25 DR. ZAGMUTT: A follow-up question about

1 that. Francisco Zagnutt. If you're talking about
2 fish, are we talking about only FSIS regulated fish,
3 catfish or salmon as well?

4 DR. SHAW: Siluriformes. So, yes.

5 DR. ZAGMUTT: Okay.

6 MS. SCOTT: This seems to extend beyond
7 microbiological contaminants. This is a
8 microbiological committee but it is your attempt to
9 deal with for example, chemical contaminants as well?

10 DR. SHAW: Well, especially when they impact
11 microbiological issues. So especially when chemical
12 contaminants can then either interact with the
13 antimicrobial treatments that are used with that
14 water, and so how they interact with each other.

15 But, yeah, I get what you're saying about,
16 you know, this micro criteria for food, but we do
17 believe that, you know, and we've seen that the
18 chemistries of antimicrobial agents that are designed
19 to kill microorganisms, they play a role in water and
20 so we can't separate that them completely. But, yes,
21 it should be a microbiological -- endeavor.

22 Yes, go ahead.

23 DR. PARISH: First of all, thank you very
24 much for a very well thought out and interesting
25 challenge for the Subcommittee. I think you did a

1 really nice job, and to your question regarding, you
2 know, FDA policies and procedures related to water, to
3 the extent that the Subcommittee's recommendations
4 might be useful for FDA regulated facilities, we'll be
5 very interested in seeing what the Subcommittee comes
6 out with. I mean if it's helpful for FDA regulated
7 plants, then we absolutely want to be open to seeing
8 what the Subcommittee comes up with for that.

9 DR. SHAW: Yeah, we just didn't want to word
10 our charge in such a way that the outcome has a bunch
11 of regulatory and rulemaking things for FDA because
12 we all know that you're immersed in your FSMA and
13 you're moving forward --

14 (Laughter).

15 DR. SHAW: You know, being in an Agency that
16 has to go through HACCP limitation, you have a -- and
17 being part of that, you have a lot -- like I have a
18 lot of -- I feel for the diverse complications and
19 challenges that go along with implementing something
20 like that, that is that big. And so I think that
21 that's why we would like to stick to our
22 establishments as much as possible with this charge.

23 DR. CARTER: Anything else?

24 (No response.)

25 DR. CARTER: Thank you, Dr. Shaw. And as I

1 said, the Committee will have plenty of opportunity to
2 discuss the charges and what we decide to work on as a
3 Subcommittee. Kis.

4 CAPT. HALE: So it looks like we're at the
5 close of the Plenary by my account. Are there any
6 other comments or anything before we look at wrapping
7 things up?

8 (No response.)

9 CAPT. HALE: I would like to thank the two
10 presenters of the charges and those that helped in
11 developing them. I think the Subcommittees will have
12 lots to think about and work on. So we will look
13 forward to the work that transpires on that. Go
14 ahead.

15 DR. HOVDE: I would like to make one quick
16 comment, and that is to thank Dr. Angela Melton-Celsa
17 who was in charge of our document from actually typing
18 it to keeping track of everyone's comments, and she
19 did a beautiful job, and I was remiss in not opening
20 my session with acknowledging her. Thanks so much,
21 Angela. We wouldn't have done it without you.

22 CAPT. HALE: Okay. Thank you. So I'll turn
23 it over to you, Mark, to adjourn us.

24 DFR. CARTER: Thanks, Kis.

25 Before we adjourn, we'll be going to lunch

1 now, and it looks like it'll be a little bit more than
2 an hour if we get back at 1:00. So it's 11:20. I
3 propose that we come back at 1:00. That gives you a
4 nice long lunchtime, and you'll have plenty of time
5 this afternoon and when we come back, we'll be meeting
6 as Subcommittees and not doing a Plenary.

7 Is Karen here to tell us which meeting rooms
8 we'll be using? Do you happen to know, Ellen?

9 All right. We'll figure that out in the
10 next hour and a half, and when you come back, you can
11 come back to this general area, and we'll have the
12 Subcommittee meetings promptly in nearby smaller
13 rooms.

14 I now call this meeting adjourned. Thank
15 you.

16 (Whereupon, at 1:21 p.m., the meeting was
17 concluded.)

18

19

20

21

22

23

24

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

C E R T I F I C A T E

This is to certify that the attached proceedings
in the matter of:

NATIONAL ADVISORY COMMITTEE ON
MICROBIOLOGICAL CRITERIA FOR FOODS

PLENARY SESSION

Washington, D.C.

August 7, 2018

were held as herein appears, and that this is the
original transcription thereof for the files of the
United States Department of Agriculture, Food Safety
and Inspection Service.



TOM BOWMAN, Reporter

FREE STATE REPORTING, INC.